10%
Chidozie Ugwumba is a prominent venture capital professional serving as Managing Partner of SymBiosis, a firm specializing in investments in biotherapeutics.[[6]](https://clene.com/member/chidozie-ugwumba/) In this role, he leads sourcing, due diligence, and execution of investments across therapeutics companies in the US and Europe, spanning areas such as CNS, cardiac, dermatology, GI, infectious disease, and oncology, including modalities like precision medicine, cell, gene, and regenerative therapy.[[6]](https://clene.com/member/chidozie-ugwumba/)
Ugwumba is recognized as a 10% Owner of Clene Inc. (NASDAQ: CLNN), a clinical-stage biopharmaceutical company developing nanoparticle therapies for neurodegenerative diseases.[[2]](https://www.marketbeat.com/instant-alerts/chidozie-ugwumba-sells-4015-shares-of-clene-nasdaqclnn-stock-2026-01-02/)[[3]](https://www.gurufocus.com/insider/177144/chidozie-ugwumba)[[7]](https://www.sahmcapital.com/news/content/10-owner-chidozie-ugwumba-reports-disposal-of-clene-inc-common-shares-2025-12-19) He holds approximately 766,480 shares, valued at over $4 million, and has recently conducted multiple sales, including 4,015 shares on January 2, 2026, at $5.73 each, 13,095 shares on December 31, 2025, and larger transactions such as 56,577 shares on December 3, 2025.[[2]](https://www.marketbeat.com/instant-alerts/chidozie-ugwumba-sells-4015-shares-of-clene-nasdaqclnn-stock-2026-01-02/)[[3]](https://www.gurufocus.com/insider/177144/chidozie-ugwumba) These trades, disclosed via SEC Form 4 filings, reflect a gradual reduction in his stake while maintaining significant ownership.[[2]](https://www.marketbeat.com/instant-alerts/chidozie-ugwumba-sells-4015-shares-of-clene-nasdaqclnn-stock-2026-01-02/)[[5]](https://www.streetinsider.com/SEC+Filings/Form++4++++++++++Clene+Inc.++++++++++++++++For:+Dec+31++Filed+by:+Ugwumba+Chidozie/25799324.html)
View full insider profile →
